PDCD1 and neoplasm: (35) combined the CSF-1R inhibitor PLX3397 with oncolytic viruses (OVs) and PD-1 antibodies and showed that CT26 and MC38 subcutaneous xenografts in 43% and 82% of mice, respectively, had complete tumor regression after combination therapy and were able to develop long-term immune memory effects.